SEC Form 4 · accession 0001567619-18-002677
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Sep 12, 2018
Accepted (ET)
Sep 14, 2018 · 6:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 12, 2018 | M | 10,000 | $1.184 | A | 145,407 | D | |
| Common StockF2,F3 | Sep 12, 2018 | S | 700 | $164.1594 | D | 144,707 | D | |
| Common StockF2,F4 | Sep 12, 2018 | S | 3,700 | $165.1821 | D | 141,007 | D | |
| Common StockF2,F5 | Sep 12, 2018 | S | 2,400 | $166.4875 | D | 138,607 | D | |
| Common StockF2,F6 | Sep 12, 2018 | S | 1,800 | $167.3814 | D | 136,807 | D | |
| Common StockF2,F7 | Sep 12, 2018 | S | 800 | $168.5125 | D | 136,007 | D | |
| Common StockF2,F8 | Sep 12, 2018 | S | 200 | $169.8872 | D | 135,807 | D | |
| Common StockF2,F9 | Sep 12, 2018 | S | 400 | $171.075 | D | 135,407 | D | |
| Common Stock | Sep 13, 2018 | M | 7,473 | $1.184 | A | 142,880 | D | |
| Common Stock | Sep 13, 2018 | M | 2,527 | $3.648 | A | 145,407 | D | |
| Common StockF2,F10 | Sep 13, 2018 | S | 5,636 | $165.425 | D | 139,771 | D | |
| Common StockF2,F11 | Sep 13, 2018 | S | 3,402 | $166.523 | D | 136,369 | D | |
| Common StockF2,F12 | Sep 13, 2018 | S | 962 | $167.3169 | D | 135,407 | D | |
| Common Stock | holding | — | — | — | 30,000 | I | By Joshua H. Bilenker, ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F13 | $1.184 | Sep 12, 2018 | M | 10,000 | D | — | Nov 14, 2023 | Common Stock | 10,000 | 63,932 | D |
| Employee Stock Option (Right to Buy)F13 | $1.184 | Sep 13, 2018 | M | 7,473 | D | — | Nov 14, 2023 | Common Stock | 7,473 | 56,459 | D |
| Employee Stock Option (Right to Buy)F14 | $3.648 | Sep 13, 2018 | M | 2,527 | D | — | Jun 18, 2024 | Common Stock | 2,527 | 92,985 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F10The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.02 to $166.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F11The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.02 to $167.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F12The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.18 to $168.1799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F13The options have fully vested and are immediately exercisable.
- F14The stock option vests and becomes exercisable in 48 equal monthly installments beginning on the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- F2Represents the aggregate of sales effected on the same day at different prices.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.75 to $164.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.75 to $165.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.02 to $167.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.04 to $168.0399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.06 to $169.0599 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.48 to $170.4799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F9The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.68 to $171.6799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.